{"id":"exl01","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Diarrhea"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"EXL01 works by inhibiting the CDK4/6 enzymes, which are involved in cell cycle progression. This inhibition leads to a decrease in cell proliferation and an increase in cell death, making it a potential therapeutic agent for cancer treatment.","oneSentence":"EXL01 is a small molecule targeting the CDK4/6 pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:52:40.796Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic breast cancer with PIK3CA mutations"}]},"trialDetails":[{"nctId":"NCT06306014","phase":"PHASE1, PHASE2","title":"Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-05-07","conditions":"Clostridioides Difficile Infection, Recurrent Infection","enrollment":56},{"nctId":"NCT07128680","phase":"PHASE1","title":"Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-01","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma","enrollment":33},{"nctId":"NCT06448572","phase":"PHASE1, PHASE2","title":"EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2024-07-16","conditions":"Non-Small Cell Lung Cancer","enrollment":21},{"nctId":"NCT06253611","phase":"PHASE2","title":"First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer","status":"RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2024-04-16","conditions":"Gastric Cancer","enrollment":120},{"nctId":"NCT06925061","phase":"PHASE2","title":"Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease","status":"RECRUITING","sponsor":"Madeleine Bezault","startDate":"2025-03-31","conditions":"Crohn Disease (CD)","enrollment":80},{"nctId":"NCT06551272","phase":"PHASE2","title":"Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Center Eugene Marquis","startDate":"2025-03-12","conditions":"Hepatocellular Carcinoma","enrollment":34},{"nctId":"NCT05542355","phase":"PHASE1","title":"EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease","status":"TERMINATED","sponsor":"Exeliom Biosciences","startDate":"2023-03-20","conditions":"Crohn Disease","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Faecalibacterium prausnitzii EXL01-strain"],"phase":"phase_2","status":"active","brandName":"EXL01","genericName":"EXL01","companyName":"GERCOR - Multidisciplinary Oncology Cooperative Group","companyId":"gercor-multidisciplinary-oncology-cooperative-group","modality":"Biologic","firstApprovalDate":"","aiSummary":"EXL01 is a small molecule targeting the CDK4/6 pathway. Used for Advanced or metastatic breast cancer with PIK3CA mutations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}